New gout pill enters first human tests
NCT ID NCT07324434
First seen Jan 09, 2026 · Last updated Jun 20, 2026 · Updated 20 times
Summary
This early-stage trial is testing a new oral drug called F-02-2-Na in 69 adults with high uric acid levels, with or without gout. The main goal is to check the drug's safety and how the body processes it at different doses. Participants will receive either the drug or a placebo, and researchers will monitor side effects and drug levels in the blood and urine.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERURICEMIA WITH OR WITHOUT GOUT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510120, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
F-02-2-Na tablet
What this could lead to
If successful, this could lead to a new oral medication to lower uric acid levels and manage gout.
What could go wrong
This is a very early Phase 1 study focused on safety and dosing, not yet testing effectiveness. The drug may not work or could have side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.